Clinuvel Pharmaceuticals Limited (ASX: CUV) - Share Price
Current share price for CUV : $9.250 0.29 (3.24%)+
CLINUVEL (CUV), an ASX-listed company, is a pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photo medicine and the family of melanocortin peptides
CUV General Information +
| ASX Code | CUV |
| Website | http://www.clinuvel.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 466 |
| CUV Share Price | $9.250 |
| Day High | $9.310 |
| Day Low | $8.920 |
| Last Close | $8.960 |
| CUV Share Price Movement | $0.29 ( 3.24% ) |
Prices as at 16:40, 15 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Clinuvel Pharmaceuticals Limited (CUV) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 5¢ | 100% | 4 Sep 2025 | 19 Sep 2025 | - | - | - |
| HFResult | 5¢ | 100% | 5 Sep 2024 | 20 Sep 2024 | - | - | - |
| HFResult | 5¢ | 100% | 5 Sep 2023 | 20 Sep 2023 | - | - | - |
See all dividends from Clinuvel Pharmaceuticals Limited (CUV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Clinuvel Pharmaceuticals Limited (CUV) price-sensitive announcements
CUV - CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
Clinuvel Pharmaceuticals Limited announced its engagement with the U.S. Securities and Exc
Clinuvel Pharmaceuticals Limited (CUV)
28 Apr 2026 | 8:50 AM
28 Apr 2026 | 8:50 AM
CUV - FDA relaxes SCENESSE postmarketing requirement
Clinuvel Pharmaceuticals Limited has announced that the U.S. FDA has reviewed and subseque
Clinuvel Pharmaceuticals Limited (CUV)
27 Apr 2026 | 8:42 AM
27 Apr 2026 | 8:42 AM
CUV - Final EMA scientific advice for pivotal Phase III vitiligo
Clinuvel Pharmaceuticals Limited has received final scientific advice from the European Me
Clinuvel Pharmaceuticals Limited (CUV)
24 Apr 2026 | 8:56 AM
24 Apr 2026 | 8:56 AM
CUV - CLINUVEL's global programs showcased at AAD
Clinuvel Pharmaceuticals Limited has showcased its global programs at the 2026 American Ac
Clinuvel Pharmaceuticals Limited (CUV)
27 Mar 2026 | 8:35 AM
27 Mar 2026 | 8:35 AM
Clinuvel Pharmaceuticals Limited (CUV) Recent ASX Announcements
CUV Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026F | $39.94 | $79.34 | 11.90% | 14.49 | 8.00 | 0.70% | 100.0% |
| 2025F | $35.68 | $70.87 | 1.10% | 16.23 | 7.00 | 0.61% | 100.0% |
| 2024A | $35.78 | $70.11 | 20.70% | 23.01 | 5.00 | 0.31% | 100.0% |
CUV Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | ||
| CSL Limited (CSL) | $51,354M | 0.1108 | -0.1365 | 0.0438 | 11.4983 | 13.3154 | 12.7567 | 4.16% | 3.34% | 3.47% |
| Clinuvel Pharmaceuticals Limited (CUV) | $446M | 0.0287 | 0.0233 | 0.0942 | 12.3259 | 12.0457 | 11.0088 | 0.56% | 0.82% | 1.32% |
| Immutep Limited (IMM) | $69M | 0.1854 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,550M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,571M | -1.3893 | 0.0000 | -0.1316 | 0.0000 | 253.1955 | 291.5584 | 0.00% | 0.00% | 0.00% |
CUV Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.20 | 12.20 | 1.86 | 2.10 |
| Market | 0.32 | 12.90 | 1.16 | 0.66 |
| Sector | 0.40 | 27.30 | 2.56 | 2.10 |
CUV Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Philippe J Wolgen | Chief Executive Officer, Managing Director | 1 Oct 2005 |
| Professor Jeffrey Rosenfeld | Non-Executive Chairman, Non-Executive Director | 26 Nov 2019 |
| Mrs Susan (Sue) Smith | Non-Executive Director | 23 Sep 2019 |
| Dr Karen Agersborg | Non-Executive Director | 29 Jan 2018 |
| Mr Matthew William Pringle | Non-Executive Director | 6 Sep 2024 |
| Dr Pearl E Grimes | Non-Executive Director | 6 Sep 2024 |
| Mr Guy van Dievoet | Non-Executive Director | 6 Sep 2024 |
Clinuvel Pharmaceuticals Limited (CUV) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 19 Sep 2023 | WOLGEN, Philippe | Buy | Direct Shares | 1,850 | $16.116 | $29,813.860 |
| 26 Jun 2023 | WOLGEN, Philippe | Buy | Direct Shares | 1,532 | $17.720 | $27,147.330 |
| 4 Nov 2022 | ROSENFELD, Jeffrey | Buy | Indirect Shares | 300 | $19.440 | $5,832.000 |
See all changes in directors' interest & trades for Clinuvel Pharmaceuticals Limited (CUV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CUV Management
| Name | Position |
|---|---|
| Mr P Vaughan | Chief Financial Officer |
| Mr L Hay | Chief Operating Officer |
| Dr D Wright | Chief Scientific Officer |
| Claire Newstead-Sinclair | Company Secretary |
CUV Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clinuvel Pharmaceuticals Limited (CUV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 3,854,043 (7.69%) | The Bank of New York Mellon Corporation |
| 3,425,222 (6.83%) | Dr Philippe Jacques Wolgen |
| 2,340,824 (4.67%) | Ender 1, LLC and SNP Ventures Group Member |
CUV Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Prelim) |
| 27 August 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
